Shares of Epizyme Inc. (NASDAQ:EPZM) fell 23.9 percent to $9.90 on Thursday after the company said it would delay submitting a new drug application for its lead candidate, tazemetostat, in epithelioid sarcoma (ES) until mid-2019 and quit testing the drug as a monotherapy in diffuse large B-cell lymphoma (DLBCL) after an interim assessment suggested the phase II study wasn't worth continuing.